

Contacts Media

Amsterdam +31 20 721 4133
Dublin +33 1 70 48 24 45
Milan +39 02 72 42 62 12
Paris +33 1 70 48 24 45

Brussels +32 2 620 15 50
Lisbon +351 210 600 614
Oslo +47 41 69 59 10

Contact Investor Relations

+33 1 70 48 24 27

EUROAPI lists on Euronext Paris

- **Market capitalisation of €1.1 billion**
- **11th company listed on Euronext Paris in 2022**
- **EUROAPI represents the largest Life Sciences listing in Europe in 2022 in terms of market capitalisation. EUROAPI is also the largest company in the pharmaceutical value chain to list on Euronext markets since 2012**



Paris – 6 May 2022 – Euronext today congratulates EUROAPI, world leader in the Active Pharmaceutical Ingredients (API) market, on its listing on Compartment A of the regulated market in Paris (ticker code: EAPI).

EUROAPI originally formed part of the Sanofi Group, which will retain 30% of the company following the operation. EPIC Bpifrance, acting on behalf of the French State under the French Tech Sovereignty convention, has undertaken to acquire 12% of EUROAPI's capital. EUROAPI is the world's leading manufacturer of small molecules and the second largest manufacturer of APIs¹. EUROAPI develops, manufactures and distributes a diversified portfolio of APIs as well as intermediates used in the formulation of medicines for human and veterinary use, both from originators and generics, through its activities "API Solutions" and "Contract Development and Manufacturing Organisation" (CDMO). The company operates six production sites in Europe and offers around 200 APIs to nearly 530 clients present in over 80 countries.

The listing of EUROAPI is part of the deployment of its strategy and its independence from Sanofi, which will remain EUROAPI's long-term strategic partner. Listing on Euronext Paris will allow the company to reinforce its API development and manufacturing capacities in Europe, serving its customers on a global scale, in order to sustainably meet the needs of patients worldwide.

EUROAPI was listed through the admission to trading, through direct listing of the 94,026,888 shares making up its equity.

The issue price of EUROAPI shares was set at €12 per share. Market capitalisation was ca. €1.1 billion at the opening of the first trading day.

Karl Rotthier, CEO of EUROAPI, said: *"This listing is an important step for EUROAPI. It aims to reinforce EUROAPI's status as reference partner for all laboratories in the pharmaceutical and the biotechnology sectors, and to build upon its independence from Sanofi. This listing will allow EUROAPI to accelerate its strategy aimed at developing the Group's activities as a CDMO, to reinforce its technological platforms, to leverage its presence in complex and highly differentiated APIs and to guarantee the Group's operational efficiency. EUROAPI is convinced that it is today well positioned to capture future growth in the dynamic API market."*

¹ Sources: estimate by EUROAPI based on market studies carried out by third parties based on data included in the annual reports published by the main industrial actors of the API sector, public databases (notably Capital IQ and Orbis) and interviews with market experts.



Caption: Karl Rotthier, CEO of EUROAPI, and his team rang the bell during a ceremony this morning in the presence of Delphine d’Amarzit, CEO of Euronext Paris, to celebrate the listing of the company.

CONTACTS EURONEXT– mediateam@euronext.com

Sarah Mound (Paris) +33 1 70 48 24 45 smound@euronext.com

CONTACTS PRESS RELATIONS EUROAPI

EUROAPI - Laurence Bollack +33 6 81 86 80 19 mr@euroapi.com

Brunswick Group - Hugues Boëton +33 6 79 99 27 15 euroapi@brunswickgroup.com
and Aude Lepreux +33 7 84 46 10 66

CONTACT INVESTOR RELATIONS EUROAPI

Guillaume Rosso +33 6 49 51 59 78 ir@euroapi.com

About EUROAPI

EUROAPI is focused on reinventing active ingredient solutions to sustainably meet customers’ and patients’ needs around the world. It is a leading player in active pharmaceutical ingredients with approximately 200 products in its portfolio, offering a large span of technologies, while developing innovative molecules through its Contract Development and Manufacturing Organisation (CDMO) activities. Taking action for health by enabling access to essential therapies inspires its 3,350 people every day. With strong research and development capabilities and six manufacturing sites all located in Europe, EUROAPI ensures API manufacturing of the highest quality to supply customers in more than 80 countries. Find out more at www.euroapi.com

About Euronext

Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With close to 2,000 listed issuers and around €6.6 trillion in market capitalisation as of end March 2022, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs. For the latest news, go to euronext.com or follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).



Disclaimer

This press release is for information purposes only: it is not a recommendation to engage in investment activities and is provided "as is", without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext's subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext. This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is available at www.euronext.com/terms-use.

© 2022, Euronext N.V. - All rights reserved.

The Euronext Group processes your personal data in order to provide you with information about Euronext (the "Purpose"). With regard to the processing of this personal data, Euronext will comply with its obligations under Regulation (EU) 2016/679 of the European Parliament and Council of 27 April 2016 (General Data Protection Regulation, "GDPR"), and any applicable national laws, rules and regulations implementing the GDPR, as provided in its privacy statement available at: www.euronext.com/privacy-policy. In accordance with the applicable legislation you have rights with regard to the processing of your personal data: for more information on your rights, please refer to: www.euronext.com/data_subjects_rights_request_information. To make a request regarding the processing of your data or to unsubscribe from this press release service, please use our data subject request form at connect2.euronext.com/form/data-subjects-rights-request or email our Data Protection Officer at dpo@euronext.com.

